Innovation That Delivers: From Vision to Patient-Centric Production

BTS is a company that was created as Spin-off from InnoMedica to focus on the further development and global sales of automation technology and software for the pharmaceutical industry.

The core of this technology is a range of highly specialized machines for the automated, sterile processing of sensitive active ingredients. These machines were originally developed by Peter Halbherr and a team of engineers for InnoMedica. While InnoMedica continues to use this technology for its own pharmaceutical applications, BTS has exclusively taken over the ongoing development, enhancement, and worldwide distribution of the machines from BTS and their associated software platforms.

InnoMedica AG was founded in the year 2000 in Zug and established itself as an operationally independent pharmaceutical company in January 2013 with the "Targeted Liposomal Doxorubicin" project. This step marked the beginning of our journey in developing innovative therapies.

Milestones of Our Development

Following a rapid initial product development phase, our focus shifted to conducting pre-clinical studies. One of the greatest challenges was the filling of the liposomal product, which would have required extraordinarily high investment costs at third-party manufacturers. Driven by the desire for independence and quality control, we made a bold decision in 2018: to build our own GMP-certified production facility in Marly near Fribourg.

Our engineering team specially developed and constructed sterile, automated filling machines for this purpose. By 2020, we had successfully tested a first, self-developed semi-automatic filling unit in production. Shortly thereafter, a second, fully automatic unit was developed, enabling continuous operation without interruption.

The Highest Standards for Patient Safety

From the very beginning, patient safety has been our highest priority, especially for the upcoming clinical tests. We implemented a comprehensive and robust quality management system, strictly adhering to the guidelines of Good Manufacturing Practice (GMP). Certification by Swissmedic confirms the high-quality standards of our production facilities in Marly.

A New Chapter: Focus Through Divestment

In 2024, Dr. Peter Halbherr, our founder and Chairman of the Board, stepped down from operational duties. As part of this strategic realignment, the exclusive marketing rights to the filling automation technologies developed by InnoMedica were transferred to BTS Business Technology & Services AG.